Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M39,564Revenue $M15,259Net Margin (%)11.1Z-Score3.2
Enterprise Value $M45,653EPS $3.7Operating Margin %14.8F-Score5
P/E(ttm))21.4Cash Flow Per Share $5.6Pre-tax Margin (%)14.2Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %12.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %6.5Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %0.3ROA % (ttm)7.3Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)22.3Less Shares Outstanding y-yY
Payout Ratio %60.0Shares Outstanding M542ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 73-2%New holding, 3397 sh.3,397
BAXRay Dalio 2014-09-30 Add0.01%$71.28 - $77
($74.81)
$ 73-2%Add 220.37%18,463
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 73-2%Sold Out0
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 73-1%Add 90872.4%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 73-1%New holding, 37150 sh.37,150
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 73-1%Reduce -30.98%123,976
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 73-1%Sold Out0
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 73-1%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 73-1%Reduce -50%3,725
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 73-1%Sold Out0
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 736%New holding, 204560 sh.204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 736%Add 13.41%179,629
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 736%New holding, 2453 sh.2,453
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 736%Reduce -85.53%1,100
BAXChris Davis 2014-03-31 Sold Out $66.49 - $72.85
($68.77)
$ 736%Sold Out0
BAXJohn Hussman 2014-03-31 Reduce-0.49%$66.49 - $72.85
($68.75)
$ 736%Reduce -93.07%7,450
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 736%Reduce -77.96%531,100
BAXRay Dalio 2014-03-31 Reduce-0.07%$66.49 - $72.85
($68.77)
$ 736%Reduce -67%62,263
BAXScott Black 2013-12-31 Add1.06%$63.89 - $69.47
($66.75)
$ 739%Add 776.11%158,392
BAXRobert Olstein 2013-12-31 Add0.15%$63.89 - $69.47
($66.75)
$ 739%Add 24.19%77,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAX David Dreman 2014-09-303,39700.02New Buy
BAX Ray Dalio 2014-09-3018,46300.01+220.37%
BAX John Keeley 2014-09-3040,6500.010.06+9.42%
BAX Charles Brandes 2014-09-30225,0230.040.21+7.2%
BAX John Rogers 2014-09-3063,0510.010.06+2.94%
BAX Scott Black 2014-09-30124,3460.021.3+0.3%
BAX Bill Nygren 2014-09-301,623,0000.30.75
BAX John Hussman 2014-09-303,72500.02
BAX Dodge & Cox 2014-09-303,38200
BAX Jean-Marie Eveillard 2014-09-30997,0560.180.18-0.36%
BAX Tweedy Browne 2014-09-302,581,2770.484.3-0.42%
BAX Mario Gabelli 2014-09-30224,9400.040.09-7.58%
BAX Robert Olstein 2014-09-30000Sold Out
BAX Bill Nygren 2014-06-301,623,0000.30.84
BAX Meridian Funds 2013-06-308,60000.02
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-3.34view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-5.95view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-5.75view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-4.74view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-2.7view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-3.83view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-0.07view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-0.98view
Bufalino Sebastian JCorporate Vice President 2014-03-27Sell21,600$75.1-3.6view
Shapazian Carole JDirector 2013-09-12Sell1,941$71.581.15view

Press Releases about BAX :

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Abbott: A Brighter Future Aug 28 2014 
Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
Why I Bought Baxter International Jun 19 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
Two Stocks On My Watch List For June 2014 May 29 2014 
Companies That Are Raising Dividends May 16 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 

More From Our Partners
NxStage Medical Unveils Streamline Express Dialyzer - Analyst Blog Nov 21 2014 - ZACKS

More From Other Websites
Finding a Margin of Safety in a Fully Valued Market Nov 21 2014
Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status Nov 20 2014
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine... Nov 19 2014
Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 13 2014
Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 13 2014
Baxter Declares Quarterly Dividend Nov 11 2014
Baxter Declares Quarterly Dividend Nov 11 2014
Nektar Therapeutics Beats on Q3 Earnings and Revenues Nov 10 2014
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer Nov 06 2014
'Mad Money' Lightning Round: Pull the Trigger on Baxter Nov 06 2014
The Thorns, Roses, All Time Highs, and ETF All Time Highs... Nov 05 2014
Baxter to Present at the Stifel 2014 Healthcare Conference Nov 05 2014
Baxter to Present at the Stifel 2014 Healthcare Conference Nov 05 2014
BAXTER INTERNATIONAL INC Financials Nov 05 2014
Seven Obamacare Bills That The New GOP Senate Majority Should Pass In 2015 Nov 05 2014
10-Q for Baxter International, Inc. Oct 31 2014
Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability... Oct 30 2014
Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability... Oct 30 2014
BAXTER INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 29 2014
Baxter International Gets FDA Nod for Hemophilia A Drug Oct 27 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 4 months ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK